We are live on
!
Find out more
GCM
Gladius Capital Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
25.75%
This Fund
S&P 500
This Quarter
Est. Return
+5.35%
1 Year Est. Return
+25.75%
3 Year Est. Return
+78.03%
5 Year Est. Return
+67.88%
10 Year Est. Return
+218.88%
AUM
$2.05B
AUM Growth
+$329M
(+19%)
Cap. Flow
+$1.88B
Cap. Flow
% of AUM
91.78%
Top 10 Holdings %
Top 10 Hldgs %
68.15%
Holding
481
New
114
Increased
102
Reduced
143
Closed
120
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$6.06M |
| 2 |
Coca-Cola
KO
|
+$3.06M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$2.91M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$2.48M |
| 5 |
Verisk Analytics
VRSK
|
+$924K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$55.5M |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$26.7M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$15M |
| 4 |
Walmart Inc
WMT
|
+$7.68M |
| 5 |
JPMorgan Chase
JPM
|
+$7.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 0.64% |
| 2 | Technology | 0.43% |
| 3 | Industrials | 0.31% |
| 4 | Communication Services | 0.28% |
| 5 | Consumer Staples | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OSG
301
Octave Specialty Group
OSG
$256M
| $21K | ﹤0.01% |
+1,476
| New | +$21.6K |
|
302
Bio-Rad Laboratories Class A
BIO
$8.92B
| $20.8K | ﹤0.01% |
+55
| New | +$22.4K |
|
|
AAN
303
DELISTED
The Aaron's Company Inc
AAN
| $20.4K | ﹤0.01% |
1,446
-1,482
| -51% | -$18.3K |
|
304
Century Therapeutics
IPSC
$372M
| $19.7K | ﹤0.01% |
6,246
-1,484
| -19% | -$4.78K |
|
305
Moderna
MRNA
$22.9B
| $19.7K | ﹤0.01% |
+162
| New | +$21.6K |
|
306
Nektar Therapeutics
NKTR
$2.44B
| $19.6K | ﹤0.01% |
+2,276
| New | +$24.3K |
|
307
Cartesian Therapeutics
RNAC
$247M
| $19.2K | ﹤0.01% |
+571
| New | +$20.4K |
|
308
Alta Equipment Group
ALTG
$240M
| $18.9K | ﹤0.01% |
1,090
-1,105
| -50% | -$16.3K |
|
309
Emergent Biosolutions
EBS
$392M
| $18.3K | ﹤0.01% |
2,492
-217
| -8% | -$2.01K |
|
|
ODP
310
DELISTED
ODP
ODP
| $17.4K | ﹤0.01% |
+371
| New | +$15.9K |
|
|
ITOS
311
DELISTED
iTeos Therapeutics
ITOS
| $17.1K | ﹤0.01% |
1,292
-424
| -25% | -$6.05K |
|
312
Atea Pharmaceuticals
AVIR
$369M
| $16.2K | ﹤0.01% |
4,330
-3,383
| -44% | -$12.7K |
|
313
RLI Corp
RLI
$5.6B
| $16.1K | ﹤0.01% |
+236
| New | +$15.7K |
|
|
PSTX
314
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $16.1K | ﹤0.01% |
+9,125
| New | +$23.3K |
|
315
Garrett Motion
GTX
$5.78B
| $16K | ﹤0.01% |
+2,110
| New | +$16.9K |
|
|
AEL
316
DELISTED
American Equity Investment Life Holding Company
AEL
| $15.4K | ﹤0.01% |
295
-491
| -62% | -$19.7K |
|
|
PENG
317
Penguin Solutions Inc
PENG
$2.96B
| $15.2K | ﹤0.01% |
525
-313
| -37% | -$6.27K |
|
318
Texas Instruments
TXN
$257B
| $15.1K | ﹤0.01% |
+84
| New | +$14.5K |
|
319
Revvity
RVTY
$12.4B
| $15K | ﹤0.01% |
126
-127
| -50% | -$15.6K |
|
320
Cato Corp
CATO
$66.7M
| $14.7K | ﹤0.01% |
1,829
-1,935
| -51% | -$16.1K |
|
321
First Financial Corp
THFF
$980M
| $14.6K | ﹤0.01% |
449
+285
| +174% | +$9.72K |
|
322
El Pollo Loco
LOCO
$504M
| $14K | ﹤0.01% |
+1,596
| New | +$14.9K |
|
323
NVE Corp
NVEC
$621M
| $12.9K | ﹤0.01% |
+132
| New | +$11.4K |
|
324
Timberland Bancorp
TSBK
$350M
| $12.6K | ﹤0.01% |
+494
| New | +$12.3K |
|
325
Invivyd
IVVD
$169M
| $12.5K | ﹤0.01% |
+11,910
| New | +$15.2K |
|
Similar funds
ACM
CCM
BFPW
PP
RIA
GACM
GA
Gladius Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Gladius Capital Management held 481 positions worth $2.05B, up 19% from $1.72B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Gladius Capital Management deployed $1.88B of net new capital in Q2 2023, opening 114 new positions and adding to 102 existing holdings. Its largest new stake was Alphabet (Google) Class C: 25,152 shares worth $3.04M.
By sector, the portfolio is most concentrated in Healthcare at 0.64% of assets, down from 1.1% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $55.5M trimmed.
- Gladius Capital Management's largest Q2 2023 buy was Alphabet (Google) Class C: 25,152 shares worth $3.04M.
- Gladius Capital Management added most to iShares Russell 2000 ETF in Q2 2023, an estimated $6.06M increase.
- Gladius Capital Management's biggest Q2 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $55.5M.
- Gladius Capital Management fully exited iShares MSCI EAFE ETF in Q2 2023, selling an estimated $26.7M.
- Gladius Capital Management's ten largest holdings make up 68% of its $2.05B portfolio in Q2 2023.
- Gladius Capital Management opened 114 new positions and closed 120 in Q2 2023.
- Gladius Capital Management's portfolio value rose 19% quarter-over-quarter to $2.05B.
Based on Gladius Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.